Skip to main content

Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

For the last one decade, scientists are working at developing nano anti-cancer drugs with the claim of ideal ones due to their targeted chemotherapic nature. These drugs have many beneficial properties such as targeted drug delivery and gene therapy modalities with minimum side effects. This article describes pros and cons and future perspectives of nano anti-cancer drugs. Efforts have been made to address the importance, special features, toxicities (general, blood identities, immune system and environmental) and future perspectives of nano anti-cancer drugs. It was concluded that nano anti-cancer drugs may be magic bullet drugs for cancer treatments leading to a bright future of the whole world.





Keywords: Deoxyribo nucleic acid; Inter Leukin-12; Inter Leukin-6; Interferon-; Multi drug resistance; Nano anti-cancer drugs; Poly ethylene glycol; Red blood corpuscles; Small interfering ribo nucleic acids; Tumor necrosis factor; White blood corpuscles; chemotherapy; dendrimers; dendritic cells; fibrosis; future perspectives; gadolinium; immune system; micelles; micro-capsules; multidrug resistance; neutropenia; paclitaxel; pros and cons; serum transaminase levels; special features; synergistic efficacy; thrombocytopenia; toxicities; tumor

Document Type: Research Article

Publication date: February 1, 2011

More about this publication?
  • Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
    Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
    As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
ben/ccdt/2011/00000011/00000002/art00002
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more